Guggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $76

Benzinga Newsdesk www.benzinga.com Positive 75.8%

Neg 0% Neu 0% Pos 75.8%

Guggenheim analyst Vamil Divan maintains Vera Therapeutics (NASDAQ:VERA) with a Buy and raises the price target from $56 to $76.